ロード中...
Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab
Palivizumab, a humanized murine monoclonal antibody that recognizes antigenic site II on both the prefusion (pre-F) and postfusion (post-F) conformations of the respiratory syncytial virus (RSV) F glycoprotein, is the only prophylactic agent approved for use for the treatment of RSV infection. Howev...
保存先:
| 出版年: | J Virol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5651723/ https://ncbi.nlm.nih.gov/pubmed/28539438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00176-17 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|